From Discovery to Decision: Building a Fit-for-Purpose Proteomics Strategy for Clinical Development
Late-stage clinical trial attrition remains one of the most expensive challenges in drug development, with more than half of Phase III programs failing to meet…
Identifying biomarkers of success: Integrated bioanalysis for glioblastoma CAR-T cell clinical trials
Glioblastoma remains one of the most aggressive and treatment-resistant cancers. Standard therapies often fail, leaving patients with limited options.…
